日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals

酸性鞘磷脂酶缺乏症和戈谢病:瘦人出现肝肿大、脾肿大和低高密度脂蛋白胆固醇的常见原因,但往往诊断不足且可治疗。

Mistry, Pramod K; Cassiman, David; Jones, Simon A; Lachmann, Robin; Lukina, Elena; Prada, Carlos E; Wasserstein, Melissa P; Thurberg, Beth L; Foster, Meredith C; Patel, Reema M; Underhill, Lisa H; Peterschmitt, M Judith

A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial

对 PUPs A-LONG 试验中既往未接受治疗的重度血友病 A 患者进行事后分析,这些患者在试验中产生了抑制剂。

Carcao, Manuel; Schiavulli, Michele; Kulkarni, Roshni; Rendo, Pablo; Foster, Meredith; Santagostino, Elena; Casiano, Sandra; Königs, Christoph

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

对重组凝血因子IX Fc融合蛋白治疗B型血友病的疗效和安全性进行事后纵向评估

Shapiro, Amy D; Kulkarni, Roshni; Ragni, Margaret V; Chambost, Hervé; Mahlangu, Johnny; Oldenburg, Johannes; Nolan, Beatrice; Ozelo, Margareth C; Foster, Meredith C; Willemze, Annemieke; Barnowski, Christopher; Jain, Nisha; Winding, Bent; Dumont, Jennifer; Lethagen, Stefan; Barnes, Chris; Pasi, K John

Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

中性粒细胞减少症、中性粒细胞增多症和中性粒细胞/淋巴细胞比值作为转移性去势抵抗性前列腺癌患者的预后标志物

Meisel, Alexander; de Wit, Ronald; Oudard, Stephane; Sartor, Oliver; Stenner-Liewen, Frank; Shun, Zhenming; Foster, Meredith; Ozatilgan, Ayse; Eisenberger, Mario; de Bono, Johann S

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results

接受eliglustat治疗4.5年后戈谢病1型患者的临床结果:3期ENGAGE试验的最终结果

Mistry, Pramod K; Lukina, Elena; Ben Turkia, Hadhami; Shankar, Suma P; Baris Feldman, Hagit; Ghosn, Marwan; Mehta, Atul; Packman, Seymour; Lau, Heather; Petakov, Milan; Assouline, Sarit; Balwani, Manisha; Danda, Sumita; Hadjiev, Evgueniy; Ortega, Andres; Foster, Meredith C; Gaemers, Sebastiaan J M; Peterschmitt, M Judith

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

卡巴他赛与阿比特龙或恩扎卢胺治疗转移性去势抵抗性前列腺癌:CARD 研究的事后分析(排除去势初治患者的化疗和内分泌治疗)

Suzuki, Hiroyoshi; Castellano, Daniel; de Bono, Johann; Sternberg, Cora N; Fizazi, Karim; Tombal, Bertrand; Wülfing, Christian; Foster, Meredith C; Ozatilgan, Ayse; Geffriaud-Ricouard, Christine; de Wit, Ronald

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials

在eliglustat临床试验期间发生意外怀孕的1型戈谢病女性的妊娠结局

Lukina, Elena; Balwani, Manisha; Belmatoug, Nadia; Watman, Nora; Hughes, Derralynn; Gaemers, Sebastiaan J M; Foster, Meredith C; Lewis, Grace; Peterschmitt, M Judith

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

凡德他尼治疗进展期和症状性甲状腺髓样癌的疗效和安全性:ZETA试验的事后分析

Kreissl, Michael C; Bastholt, Lars; Elisei, Rossella; Haddad, Robert; Hauch, Ole; Jarząb, Barbara; Robinson, Bruce; Colzani, Raffaella; Foster, Meredith; Weiss, Richard; Schlumberger, Martin

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial

接受eliglustat治疗8年后,戈谢病1型患者的疗效:II期试验的最终结果

Lukina, Elena; Watman, Nora; Dragosky, Marta; Lau, Heather; Avila Arreguin, Elsa; Rosenbaum, Hanna; Zimran, Ari; Foster, Meredith C; Gaemers, Sebastiaan J M; Peterschmitt, M Judith

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

已完成的四项口服eliglustat治疗1型戈谢病成人患者的试验的长期不良事件概况

Peterschmitt, M Judith; Freisens, Selena; Underhill, Lisa H; Foster, Meredith C; Lewis, Grace; Gaemers, Sebastiaan J M